Ainos (NASDAQ:AIMD – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Earnings & Valuation
This table compares Ainos and Profound Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ainos | $120,000.00 | 122.83 | -$14.77 million | ($2.89) | -0.60 |
| Profound Medical | $16.10 million | 14.67 | -$42.57 million | ($1.24) | -5.24 |
Risk & Volatility
Ainos has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
Profitability
This table compares Ainos and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ainos | -11,912.10% | -160.55% | -62.29% |
| Profound Medical | -206.76% | -78.88% | -64.06% |
Analyst Ratings
This is a summary of current recommendations and price targets for Ainos and Profound Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ainos | 1 | 0 | 0 | 0 | 1.00 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Profound Medical has a consensus target price of $12.00, indicating a potential upside of 84.62%. Given Profound Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Ainos.
Insider and Institutional Ownership
47.9% of Profound Medical shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Profound Medical beats Ainos on 8 of the 14 factors compared between the two stocks.
About Ainos
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.
